[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cancer Market Research Reports & Industry Analysis

Cancer is a package of diseases marked by uncurbed growth and proliferation of anomalous cells. The illness is generally assumed to be the fruit of the impact of assorted outside factors and inner forces, such as tobacco smoking, radiation exposure, chemicals’ influences, infectious agents, inherited gene mutations, hormonal disorders, immune system conditions and mutations of other origins, among others.

Thus far, the Cancer Market has already seen noticeable progress in early-stage tumor detection and cure globally. The market for Cancer diagnostics is close to explosive growth, promising to reach approximately EUR 4 billion in value by end-2015. Further, technology discoveries will continue to afford many chances of demystifying the genetic components of the sickness, identifying specific tumor types, and observing biological reaction to cancer treatments. However, the bulk of presently available therapies do not fully protect against some unwelcomed side-effects.

The research reports in this Catalogue present global, regional and nation-level analyses of the Cancer Market development trends over different time spans. The research reports identify major bizopps emerging in the Cancer Market; examine versatile Cancer diagnostic test technologies along with their applications, besides looking into other Cancer Market issues. The research reports also profile the top players and would-be entrants, as well as offer test volume and sales projections.

Publications found: 1,864
Sort by:

2012 Spain Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies

US$ 4,320.00

This report presents a comprehensive analysis of the Spanish cancer diagnostics market, including: Major issues pertaining to the Spanish laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Mortality ...

April 2012 565 pages

2012 UK Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies

US$ 4,320.00

This report presents a comprehensive analysis of the UK cancer diagnostics market, including: Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Mortality ...

April 2012 620 pages

The 2012 Cancer Diagnostics Market: New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks

US$ 680.00

The report identifies major opportunities emerging in the cancer diagnostics market during the next ten years; proposes “ideal” product models with tentative prices and operating characteristics; and suggests alternative business expansion strategies for suppliers. Contains 15 pages

March 2012 15 pages

Cancer Monoclonal Antibodies Market to 2015

US$ 1,500.00

Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In...

February 2012 105 pages

Emerging Opportunities in Cancer Nucleic Acid Testing

US$ 1,160.00

The report presents an overview of the clinical significance and market needs for major tumor markers, as well as listings of companies developing and marketing NAT technologies and products for cancer testing. Contains 45 pages

February 2012 45 pages

Future Italian Tumor Marker Testing Market Outlook

US$ 4,320.00

... Comprehensive 570-page analysis of the Italian tumor marker testing market. Major issues pertaining to the Italian laboratory practice, as well as key ... volume and sales forecasts for over 40 tumor marker performed in Italian hospitals and commercial laboratories. Placements and installed base of automated ...

February 2012 570 pages

World Cancer Diagnostics Market Key Players: Strategic Assessments of Major Suppliers and Emerging Market Entrants

US$ 2,000.00

This report presents strategic analyses of major current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Contains 80 pages

December 2011 80 pages

Future Cancer Diagnostic Technologies and Market Applications

US$ 1,480.00

... , immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy. Contains 110 pages

December 2011 110 pages

Global Prostate Cancer Therapeutics Market (2010 – 2020) (Opportunity Analysis, Pipeline Assessment & Market Forecast)

US$ 3,955.00

... of about 2% of the overall prostate cancer therapeutics market. As far as drugs are concerned, Taxotere accounted for 23% of the total sales of prostate cancer drugs in 2010. Astrazeneca PLC ... to September 2011. Scope of the report The prostate cancer therapeutics market research report evaluates the global prostate cancer drugs market with respect to the current and ...

November 2011 286 pages

World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition, The

US$ 3,500.00

... Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition - focuses on several segments for cancer treatment including: ... complete research effort into the oncology treatments market in the past ten years, provides market size information for the various types of ...

October 2011 245 pages

Cancer Therapies: Market Research Report

US$ 4,500.00

... report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy. ... 2017. A six-year historic analysis is also provided for these markets. The report profiles 152 companies including many key and ...

October 2011 897 pages

Roche, GlaxoSmithKline - ALTTO trial- Tykerb alone arm discontinuation- Read-through for Head to Head Study vs. Herceptin in First line HER2+ve Breast Cancer setting

US$ 90.00

Based on a planned interim review of early data from ALTTO (Adjuvant lapatinib and/or Trastuzumab Treatment Optimization trial), a Phase III, four arm study of adjuvant ... hence has recommended patients assigned to Tykerb alone arm of the trial should discontinue. While DSMB has asked patients on the rest ...

September 2011 1 pages

ONYX PHARMA - Testing Time Ahead in the Hematological Cancer Space

US$ 140.00

... read our report released on 2nd September, 2011 on ONXX titled “Testing Time Ahead in the Hematological Cancer Space”.

September 2011 3 pages

Looking at the Cancer Therapy Market

US$ 200.00

... presents a comprehensive research report – Looking at the Cancer Therapy Market – which analyzes the global cancer market. Explaining the basics of cancer, to the treatments available and ...

June 2011 60 pages

Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey

US$ 500.00

... patient specific case scenario on advanced lung cancer in a situation involving a smoker with squamous cell that progresses throughout the report, presented ... cancer. This report allows you to: Understand what occurs with actual patients Access the most up-to-date prescribing trends Gain actionable data ...

April 2011 25 pages

Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

US$ 500.00

A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the ... that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in ...

April 2011 33 pages

Advanced Lung Cancer in Patient Light Smoker with Lung Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

US$ 2,999.00

Global Site License Price: US$ 4,999.00 A patient specific case scenario on advanced lung cancer in a situation involving a patient that is a light smoker with lung adenocarcinoma that progresses thro...

April 2011 28 pages

US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer

US$ 1,200.00

... to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment ... with adenocarcinoma Former light smoker whose cancer is EGFR positive Treatment decisions for advanced stages of cancer are difficult to track as information ...

April 2011 56 pages

The Cancer Diagnostics Market new Product Development Opportunites and Business Expansion Strategies for Instrument and Reagent Suppliers

US$ 22,800.00

... and much more. The 2009 edition of the report, "The Cancer Diagnostics Market: New Product Development and Business Strategies," is being updated by ... banking community in the U.S., five major European countries and Japan.The market projections are also based on questionnaire responses received from hospitals, ...

April 2011 1200 pages

Advanced Prostate Cancer with Increased PSA and Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

US$ 500.00

... prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer. Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and ...

March 2011 35 pages

Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey

US$ 500.00

... for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors ... are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer. Treatment decisions for advanced stages ...

March 2011 24 pages

US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer

US$ 1,200.00

... that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open ... , barriers to optimal care, and confidence in treatment. Patients include: Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for ...

March 2011 52 pages

Competitor Analysis: Cancer Antibodies in Early Clinical Development

US$ 1,210.00

... CD20, VEGF and Her2, but also of many new and unique antibodies directed against novel targets which will have to show its ... cancer. In addition, the report lists company-specific R&D pipelines of anti-cancer antibodies. Competitor projects are listed in a tabular format providing information on: Drug Codes, ...

February 2011 183 pages

Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer

US$ 500.00

Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening ...

February 2011 59 pages

US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer

US$ 1,200.00

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at ...

January 2011 59 pages

Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

US$ 500.00

... patient case scenario that unfolds throughout the report, presented to high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their clinical decisions. Out of 174 oncologists’ responses, those who use combination chemotherapy were most likely to use xx and ...

January 2011 36 pages

Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

US$ 500.00

... the report, presented to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on clinical decisions. Patient ... the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open responses on clinical decisions. ...

January 2011 30 pages

US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer

US$ 500.00

... that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open ... , barriers to optimal care, and confidence in treatment. Patients include: Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for ...

January 2011 31 pages

Bladder Cancer Therapeutics: Market Research Report

US$ 3,950.00

This report analyzes the worldwide markets for Bladder Cancer Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, Japan, ... many key and niche players such as Affitech A/S, Allergan, Inc., Allos Therapeutics, Inc., Astellas Pharma, Inc., Astrazeneca Plc, AVI BioPharma, Inc., ...

October 2010 580 pages

Bladder Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Bladder Cancer Therapy Area Pipeline Report contains detailed information on the bladder cancer drug pipeline. This report provides insight into the pipeline status of bladder...

September 2010 141 pages

Breast Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Breast Cancer Therapy Area Pipeline Report contains detailed information on the breast cancer drug pipeline. This report provides insight into the pipeline status of breast ca...

September 2010 1178 pages

Cervical Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Cervical Cancer Therapy Area Pipeline Report contains detailed information on the cervical cancer drug pipeline. This report provides insight into the pipeline status of cervi...

September 2010 120 pages

Colorectal and Colon Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Colorectal and Colon Cancer Therapy Area Pipeline Report contains detailed information on the colorectal and colon cancer drug pipeline. This report provides insight into the...

September 2010 957 pages

Gastrointestinal (Stomach) Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Gastrointestinal (Stomach) Cancer Therapy Area Pipeline Report contains detailed information on the gastrointestinal (stomach) cancer drug pipeline. This report provides insig...

September 2010 270 pages

Head and Neck Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Head and Neck Cancer Therapy Area Pipeline Report contains detailed information on the head and neck cancer drug pipeline. This report provides insight into the pipeline statu...

September 2010 423 pages

Kidney Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Kidney Cancer Therapy Area Pipeline Report contains detailed information on the kidney cancer drug pipeline. This report provides insight into the pipeline status of kidney ca...

September 2010 431 pages

Liver Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Liver Cancer Therapy Area Pipeline Report contains detailed information on the liver cancer drug pipeline. This report provides insight into the pipeline status of liver cance...

September 2010 419 pages

Lung Cancer and Non-Small Cell Lung Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Lung Cancer and Non-Small Cell Lung Cancer Therapy Area Pipeline Report contains detailed information on the lung cancer and non-small cell lung cancer drug pipeline. This rep...

September 2010 1397 pages

Ovarian Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Ovarian Cancer Therapy Area Pipeline Report contains detailed information on the ovarian cancer drug pipeline. This report provides insight into the pipeline status of ovarian...

September 2010 589 pages

Pancreatic Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Pancreatic Cancer Therapy Area Pipeline Report contains detailed information on the pancreatic cancer drug pipeline. This report provides insight into the pipeline status of p...

September 2010 403 pages

Prostate Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Prostate Cancer Therapy Area Pipeline Report contains detailed information on the prostate cancer drug pipeline. This report provides insight into the pipeline status of prost...

September 2010 847 pages

Skin Cancer and Melanoma Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Skin Cancer and Melanoma Therapy Area Pipeline Report contains detailed information on the skin cancer and melanoma drug pipeline. This report provides insight into the pipeli...

September 2010 550 pages

Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025

US$ 2,325.00

... informed opinion to benefit your work. Why you should buy Monoclonal Antibodies in Cancer Therapy: World Market Prospects 2010-2025 This report gives ... our survey. This report is essential reading for anybody interested in the cancer drug industry and market. With expanding patient populations and unmet ...

June 2010 107 pages

Cancer Bladder Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Bladder Cancer Therapy Area Pipeline Report contains detailed information on the bladder cancer drug pipeline. This report provides insight into the pipeline status of bladder...

January 2010 138 pages

Cancer Brain Tumor Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Brain Tumor Therapy Area Pipeline Report contains detailed information on the brain tumor drug pipeline. This report provides insight into the pipeline status of brain tumor d...

January 2010 373 pages

Cancer Breast Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Breast Cancer Therapy Area Pipeline Report contains detailed information on the breast cancer drug pipeline. This report provides insight into the pipeline status of breast ca...

January 2010 1119 pages

Cancer Colorectal Cancer or Colon Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Colorectal Cancer or Colon Cancer Therapy Area Pipeline Report contains detailed information on the colorectal cancer or colon cancer drug pipeline. This report provides insig...

January 2010 877 pages

Cancer Gastrointestinal (Stomach) Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Gastrointestinal (Stomach) Cancer Therapy Area Pipeline Report contains detailed information on the gastrointestinal (stomach) cancer drug pipeline. This report provides insig...

January 2010 235 pages

Cancer Head and Neck Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Head and Neck Cancer Therapy Area Pipeline Report contains detailed information on the head and neck cancer drug pipeline. This report provides insight into the pipeline statu...

January 2010 406 pages

Cancer Kidney Cancer Therapy Area Pipeline Report

US$ 1,495.00

Life Science Analytics', Kidney Cancer Therapy Area Pipeline Report contains detailed information on the kidney cancer drug pipeline. This report provides insight into the pipeline status of kidney ca...

January 2010 391 pages

Filters

Search

Publishers

4
3
1
14
2
2
26
10
1
3
1
1
6
9
10
2
4
10
20
5
97
8
3
100
7
1
8
3
1
1
6
12
2
1
11
18
8
1
4
12
1
5
4
11
43
7
2
1,108
5
25
2
73
17
10
23
12
5
1
10
17
2
30
4
9

Regions

26
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
4
11
5
5
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
27
7
7
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
5
5
5
19
21
8
7
71
55
54
54
53
52
53
102
840

Price

Date

Pages

Offers

3
4
1